◼ Archived
Business
Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets
Neurosterix, spun out from Addex Therapeutics, secures $105 million Series B to advance a schizophrenia candidate and recruits executives from Karuna Therapeutics' Cobenfy program.